Replies to post #559607 on NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

Eagle, I agree 100%. With MHRA approval on the horizon, it's impossible to believe that pps %-wise appreciation will not beat the pants off the dilution rate from here. Yes, more cash will be burned before approval is granted, perhaps even $70-100M, but I can't see MHRA demanding another ph 3 trial before granting marketing approval. With approval, even in the UK, I believe a fair price has to be $2/shr or more, just for starters. Hence short of requiring another full ph 3 trial, the math is totally on the side of being long, IMO. It's really a no-brainer.